{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T23:28:03Z","timestamp":1793662083740,"version":"4.5.1"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,1,5]],"date-time":"2019-01-05T00:00:00Z","timestamp":1546646400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arthritis Res Ther"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1186\/s13075-018-1793-7","type":"journal-article","created":{"date-parts":[[2019,1,5]],"date-time":"2019-01-05T12:26:47Z","timestamp":1546691207000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":53,"title":["Safety and efficacy of infliximab in the treatment of refractory uveoretinitis in Beh\u00e7et\u2019s disease: a large-scale, long-term postmarketing surveillance in Japan"],"prefix":"10.1186","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6964-6094","authenticated-orcid":false,"given":"Shigeaki","family":"Ohno","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Itsuro","family":"Umebayashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miyuki","family":"Matsukawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Goto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshiro","family":"Yano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,1,5]]},"reference":[{"key":"1793_CR1","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1016\/0039-6257(82)90079-0","volume":"26","author":"JB Michelson","year":"1982","unstructured":"Michelson JB, Chisari FV. Beh\u00e7et\u2019s disease. Surv Ophthalmol. 1982;26:190\u2013203.","journal-title":"Surv Ophthalmol"},{"key":"1793_CR2","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1016\/S0002-9394(00)00659-0","volume":"130","author":"DA Jabs","year":"2000","unstructured":"Jabs DA, Rosenbaum JT, Foster CS, Holland GN, Jaffe GJ, Louie JS, et al. Guidelines for the use of immunosuppressive drugs in patients with ocular inflammatory disorders: recommendations of an expert panel. Am J Ophthalmol. 2000;130:492\u2013513.","journal-title":"Am J Ophthalmol"},{"key":"1793_CR3","first-page":"3884","volume":"35","author":"S Nakamura","year":"1994","unstructured":"Nakamura S, Yamakawa T, Sugita M, Kijima M, Ishioka M, Tanaka S, et al. The role of tumor necrosis factor-alpha in the induction of experimental autoimmune uveoretinitis in mice. Invest Ophthalmol Vis Sci. 1994;35:3884\u20139.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"1793_CR4","first-page":"2211","volume":"37","author":"G Sartani","year":"1996","unstructured":"Sartani G, Silver PB, Rizzo LV, Chan CC, Wiggert B, Mastorakos G, et al. Anti-tumor necrosis factor alpha therapy suppresses the induction of experimental autoimmune uveoretinitis in mice by inhibiting antigen priming. Invest Ophthalmol Vis Sci. 1996;37:2211\u20138.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"1793_CR5","first-page":"1282","volume":"96","author":"S Nakamura","year":"1992","unstructured":"Nakamura S, Sugita M, Tanaka S, Ohno S. Enhanced production of in vitro tumor necrosis factor-alpha from monocytes in Beh\u00e7et\u2019s disease. Nippon Ganka Gakkai Zasshi. 1992;96:1282\u20135.","journal-title":"Nippon Ganka Gakkai Zasshi"},{"key":"1793_CR6","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1006\/cyto.1995.1003","volume":"7","author":"SA Siegel","year":"1995","unstructured":"Siegel SA, Shealy DJ, Nakada MT, Le J, Woulfe DS, Probert L, et al. The mouse\/human chimeric monoclonal antibody cA2 neutralizes TNF in vitro and protects transgenic mice from cachexia and TNF lethality in vivo. Cytokine. 1995;7:15\u201325.","journal-title":"Cytokine"},{"key":"1793_CR7","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1006\/cyto.1995.0029","volume":"7","author":"BJ Scallon","year":"1995","unstructured":"Scallon BJ, Moore MA, Trinh H, Knight DM, Ghrayeb JJ. Chimeric anti-TNF-alpha monoclonal antibody cA2 binds recombinant transmembrane TNF-alpha and activates immune effector functions. Cytokine. 1995;7:251\u20139.","journal-title":"Cytokine"},{"key":"1793_CR8","doi-asserted-by":"publisher","first-page":"1932","DOI":"10.1016\/S0140-6736(99)05246-0","volume":"354","author":"R Maini","year":"1999","unstructured":"Maini R, St Clair EW, Breedveld F, Furst D, Kalden J, Weisman M, et al. Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group. Lancet. 1999;354:1932\u20139.","journal-title":"Lancet"},{"key":"1793_CR9","doi-asserted-by":"publisher","first-page":"1541","DOI":"10.1016\/S0140-6736(02)08512-4","volume":"359","author":"SB Hanauer","year":"2002","unstructured":"Hanauer SB, Feagan BG, Lichtenstein GR, Mayer LF, Schreiber S, Colombel JF, et al. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet. 2002;359:1541\u20139.","journal-title":"Lancet"},{"key":"1793_CR10","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1016\/j.jaad.2004.02.021","volume":"51","author":"AB Gottlieb","year":"2004","unstructured":"Gottlieb AB, Evans R, Li S, Dooley LT, Guzzo CA, Baker D, et al. Infliximab induction therapy for patients with severe plaque-type psoriasis: a randomized, double-blind, placebo-controlled trial. J Am Acad Dermatol. 2004;51:534\u201342.","journal-title":"J Am Acad Dermatol"},{"key":"1793_CR11","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1002\/art.20852","volume":"52","author":"D Heijde van der","year":"2005","unstructured":"van der Heijde D, Dijkmans B, Geusens P, Sieper J, DeWoody K, Williamson P, et al. Efficacy and safety of infliximab in patients with ankylosing spondylitis: results of a randomized, placebo-controlled trial (ASSERT). Arthritis Rheum. 2005;52:582\u201391.","journal-title":"Arthritis Rheum"},{"key":"1793_CR12","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.1002\/art.20967","volume":"52","author":"CE Antoni","year":"2005","unstructured":"Antoni CE, Kavanaugh A, Kirkham B, Tutuncu Z, Burmester GR, Schneider U, et al. Sustained benefits of infliximab therapy for dermatologic and articular manifestations of psoriatic arthritis: results from the infliximab multinational psoriatic arthritis controlled trial (IMPACT). Arthritis Rheum. 2005;52:1227\u201336.","journal-title":"Arthritis Rheum"},{"key":"1793_CR13","doi-asserted-by":"publisher","first-page":"2462","DOI":"10.1056\/NEJMoa050516","volume":"353","author":"P Rutgeerts","year":"2005","unstructured":"Rutgeerts P, Sandborn WJ, Feagan BG, Reinisch W, Olson A, Johanns J, et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2005;353:2462\u201376.","journal-title":"N Engl J Med"},{"key":"1793_CR14","doi-asserted-by":"publisher","first-page":"1994","DOI":"10.1038\/s41598-017-18387-7","volume":"8","author":"M Mori","year":"2018","unstructured":"Mori M, Hara T, Kikuchi M, Shimizu H, Miyamoto T, Iwashima S, et al. Infliximab versus intravenous immunoglobulin for refractory Kawasaki disease: a phase 3, randomized, open-label, active-controlled, parallel-group, multicenter trial. Sci Rep. 2018;8:1994.","journal-title":"Sci Rep"},{"key":"1793_CR15","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1016\/j.autrev.2007.03.009","volume":"6","author":"F Atzeni","year":"2007","unstructured":"Atzeni F, Doria A, Carrabba M, Turiel M, Sarzi-Puttini P. Potential target of infliximab in autoimmune and inflammatory diseases. Autoimmun Rev. 2007;6:529\u201336.","journal-title":"Autoimmun Rev"},{"key":"1793_CR16","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1016\/S0140-6736(01)05497-6","volume":"358","author":"PP Sfikakis","year":"2001","unstructured":"Sfikakis PP, Theodossiadis PG, Katsiari CG, Kaklamanis P, Markomichelakis NN. Effect of infliximab on sight-threatening panuveitis in Beh\u00e7et's disease. Lancet. 2001;358:295\u20136.","journal-title":"Lancet"},{"key":"1793_CR17","first-page":"5","volume":"6","author":"F Cantini","year":"2012","unstructured":"Cantini F, Niccoli L, Nannini C, Kaloudi O, Cassar\u00e0 E, Susini M, et al. Efficacy of infliximab in refractory Beh\u00e7et's disease-associated and idiopathic posterior segment uveitis: a prospective, follow-up study of 50 patients. Biologics. 2012;6:5\u201312.","journal-title":"Biologics"},{"key":"1793_CR18","first-page":"1362","volume":"31","author":"S Ohno","year":"2004","unstructured":"Ohno S, Nakamura S, Hori S, Shimakawa M, Kawashima H, Mochizuki M, et al. Efficacy, safety, and pharmacokinetics of multiple administration of infliximab in Beh\u00e7et's disease with refractory uveoretinitis. J Rheumatol. 2004;31:1362\u20138.","journal-title":"J Rheumatol"},{"issue":"Suppl 1","key":"1793_CR19","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.3109\/09273948.2014.981547","volume":"23","author":"K Namba","year":"2015","unstructured":"Namba K, Goto H, Kaburaki T, Kitaichi N, Mizuki N, Asukata Y, et al. A Major Review: current aspects of ocular Beh\u00e7et's disease in Japan. Ocul Immunol Inflamm. 2015;23(Suppl 1):S1\u201323.","journal-title":"Ocul Immunol Inflamm"},{"key":"1793_CR20","first-page":"394","volume":"116","author":"Committee for the Preparation of Clinical Treatment of Ocular Lesions Related to Behcet's Disease","year":"2012","unstructured":"Committee for the Preparation of Clinical Treatment of Ocular Lesions Related to Behcet's Disease. Guidelines for the clinical management of ocular Beh\u00e7et's disease. Nippon Ganka Gakkai Zasshi. 2012;116:394\u2013426.","journal-title":"Nippon Ganka Gakkai Zasshi"},{"key":"1793_CR21","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1136\/bjo.2009.158840","volume":"94","author":"Y Yamada","year":"2010","unstructured":"Yamada Y, Sugita S, Tanaka H, Kamoi K, Kawaguchi T, Mochizuki M. Comparison of infliximab versus ciclosporin during the initial 6-month treatment period in Beh\u00e7et disease. Br J Ophthalmol. 2010;94:284\u20138.","journal-title":"Br J Ophthalmol"},{"key":"1793_CR22","first-page":"87","volume":"114","author":"H Tanaka","year":"2010","unstructured":"Tanaka H, Sugita S, Yamada Y, Kawaguchi T, Iwanaga Y, Kamoi K, et al. Effects and safety of infliximab administration in refractory uveoretinitis with Beh\u00e7et's disease. Nippon Ganka Gakkai Zasshi. 2010;114:87\u201395.","journal-title":"Nippon Ganka Gakkai Zasshi"},{"key":"1793_CR23","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1001\/archophthalmol.2011.2698","volume":"130","author":"AA Okada","year":"2012","unstructured":"Okada AA, Goto H, Ohno S, Mochizuki M. Multicenter study of infliximab for refractory uveoretinitis in Beh\u00e7et disease. Arch Ophthalmol. 2012;130:592\u20138.","journal-title":"Arch Ophthalmol"},{"key":"1793_CR24","doi-asserted-by":"publisher","first-page":"1877","DOI":"10.1016\/j.ophtha.2014.04.042","volume":"121","author":"M Takeuchi","year":"2014","unstructured":"Takeuchi M, Kezuka T, Sugita S, Keino H, Namba K, Kaburaki T, et al. Evaluation of the long-term efficacy and safety of infliximab treatment for uveitis in Beh\u00e7et's disease: a multicenter study. Ophthalmology. 2014;121:1877\u201384.","journal-title":"Ophthalmology"},{"key":"1793_CR25","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1080\/09273948.2016.1239746","volume":"25","author":"H Keino","year":"2017","unstructured":"Keino H, Okada AA, Watanabe T, Nakayama M, Nakamura T. Efficacy of infliximab for early remission induction in refractory uveoretinitis associated with Beh\u00e7et disease: a 2-year follow-up study. Ocul Immunol Inflamm. 2017;25:46\u201351.","journal-title":"Ocul Immunol Inflamm"},{"key":"1793_CR26","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1007\/s00296-008-0606-8","volume":"29","author":"H Al-Rayes","year":"2008","unstructured":"Al-Rayes H, Al-Swailem R, Al-Balawi M, Al-Dohayan N, Al-Zaidi S, Tariq M. Safety and efficacy of infliximab therapy in active Behcet's uveitis: an open-label trial. Rheumatol Int. 2008;29:53\u20137.","journal-title":"Rheumatol Int"},{"key":"1793_CR27","doi-asserted-by":"publisher","first-page":"1161","DOI":"10.1093\/rheumatology\/kem101","volume":"46","author":"L Niccoli","year":"2007","unstructured":"Niccoli L, Nannini C, Benucci M, Chindamo D, Cassar\u00e0 E, Salvarani C, et al. Long-term efficacy of infliximab in refractory posterior uveitis of Beh\u00e7et's disease: a 24-month follow-up study. Rheumatology (Oxford). 2007;46:1161\u20134.","journal-title":"Rheumatology (Oxford)"},{"key":"1793_CR28","doi-asserted-by":"publisher","first-page":"2478","DOI":"10.1002\/art.21231","volume":"52","author":"I Tugal-Tutkun","year":"2005","unstructured":"Tugal-Tutkun I, Mudun A, Urgancioglu M, Kamali S, Kasapoglu E, Inanc M, et al. Efficacy of infliximab in the treatment of uveitis that is resistant to treatment with the combination of azathioprine, cyclosporine, and corticosteroids in Beh\u00e7et's disease: an open-label trial. Arthritis Rheum. 2005;52:2478\u201384.","journal-title":"Arthritis Rheum"},{"key":"1793_CR29","doi-asserted-by":"publisher","first-page":"2223","DOI":"10.1093\/rheumatology\/keu266","volume":"53","author":"V Calvo-R\u00edo","year":"2014","unstructured":"Calvo-R\u00edo V, Blanco R, Beltr\u00e1n E, S\u00e1nchez-Burs\u00f3n J, Mesquida M, Ad\u00e1n A, et al. Anti-TNF-\u03b1 therapy in patients with refractory uveitis due to Beh\u00e7et's disease: a 1-year follow-up study of 124 patients. Rheumatology (Oxford). 2014;53:2223\u201331.","journal-title":"Rheumatology (Oxford)"},{"key":"1793_CR30","doi-asserted-by":"publisher","first-page":"1522","DOI":"10.1002\/art.39667","volume":"68","author":"H Vallet","year":"2016","unstructured":"Vallet H, Seve P, Biard L, Baptiste Fraison JB, Bielefeld P, Perard L, et al. Infliximab versus adalimumab in the treatment of refractory inflammatory uveitis: a multicenter study from the French Uveitis Network. Arthritis Rheumatol. 2016;68:1522\u201330.","journal-title":"Arthritis Rheumatol"},{"key":"1793_CR31","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1136\/ard.2007.072967","volume":"67","author":"T Takeuchi","year":"2008","unstructured":"Takeuchi T, Tatsuki Y, Nogami Y, Ishiguro N, Tanaka Y, Yamanaka H, et al. Postmarketing surveillance of the safety profile of infliximab in 5000 Japanese patients with rheumatoid arthritis. Ann Rheum Dis. 2008;67:189\u201394.","journal-title":"Ann Rheum Dis"},{"key":"1793_CR32","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1111\/1346-8138.13214","volume":"43","author":"H Torii","year":"2016","unstructured":"Torii H, Terui T, Matsukawa M, Takesaki K, Ohtsuki M, Nakagawa H, et al. Safety profiles and efficacy of infliximab therapy in Japanese patients with plaque psoriasis with or without psoriatic arthritis, pustular psoriasis or psoriatic erythroderma: results from the prospective post-marketing surveillance. J Dermatol. 2016;43:767\u201378.","journal-title":"J Dermatol"},{"key":"1793_CR33","doi-asserted-by":"publisher","first-page":"R121","DOI":"10.1186\/ar3058","volume":"12","author":"I Delabaye","year":"2010","unstructured":"Delabaye I, De Keyser F. REMITRACT study group. 74-week follow-up of safety of infliximab in patients with refractory rheumatoid arthritis. Arthritis Res Ther. 2010;12:R121.","journal-title":"Arthritis Res Ther"},{"key":"1793_CR34","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1093\/rheumatology\/keq242","volume":"50","author":"JB Galloway","year":"2011","unstructured":"Galloway JB, Hyrich KL, Mercer LK, Dixon WG, Fu B, Ustianowski AP, et al. Anti-TNF therapy is associated with an increased risk of serious infections in patients with rheumatoid arthritis especially in the first 6 months of treatment: updated results from the British Society for Rheumatology Biologics Register with special emphasis on risks in the elderly. Rheumatology (Oxford). 2011;50:124\u201331.","journal-title":"Rheumatology (Oxford)"},{"key":"1793_CR35","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1002\/acr.21666","volume":"64","author":"R Sakai","year":"2012","unstructured":"Sakai R, Komano Y, Tanaka M, Nanki T, Koike R, Nagasawa H, et al. Time-dependent increased risk for serious infection from continuous use of tumor necrosis factor antagonists over three years in patients with rheumatoid arthritis. Arthritis Care Res (Hoboken). 2012;64:1125\u201334.","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"suppl II","key":"1793_CR36","first-page":"189","volume":"66","author":"T Takeuchi","year":"2007","unstructured":"Takeuchi T, Tatsuki T, Murakami S, Nogami Y, Koike T. Serious infectious diseases associated with infliximab treatment in 5,000 Japanese rheumatoid arthritis patients followed prospectively in the post-marketing surveillance study (PMS). Ann Rheum Dis. 2007;66(suppl II):189.","journal-title":"Ann Rheum Dis"},{"key":"1793_CR37","doi-asserted-by":"publisher","first-page":"343","DOI":"10.3109\/s10165-010-0406-3","volume":"21","author":"T Koike","year":"2011","unstructured":"Koike T, Harigai M, Inokuma S, Ishiguro N, Ryu J, Takeuchi T, et al. Postmarketing surveillance of safety and effectiveness of etanercept in Japanese patients with rheumatoid arthritis. Mod Rheumatol. 2011;21:343\u201351.","journal-title":"Mod Rheumatol"},{"key":"1793_CR38","doi-asserted-by":"publisher","first-page":"390","DOI":"10.3109\/14397595.2013.843760","volume":"24","author":"T Koike","year":"2014","unstructured":"Koike T, Harigai M, Ishiguro N, Inokuma S, Takei S, Takeuchi T, et al. Safety and effectiveness of adalimumab in Japanese rheumatoid arthritis patients: postmarketing surveillance report of 7740 patients. Mod Rheumatol. 2014;24:390\u20138.","journal-title":"Mod Rheumatol"},{"key":"1793_CR39","doi-asserted-by":"publisher","first-page":"1375","DOI":"10.1016\/j.jid.2017.01.030","volume":"137","author":"SM Langan","year":"2017","unstructured":"Langan SM, Abuabara K, Henrickson SE, Hoffstad O, Margolis DJ. Increased risk of cutaneous and systemic infections in atopic dermatitis-a cohort study. J Invest Dermatol. 2017;137:1375\u20137.","journal-title":"J Invest Dermatol"},{"key":"1793_CR40","doi-asserted-by":"publisher","first-page":"1098","DOI":"10.1056\/NEJMoa011110","volume":"345","author":"J Keane","year":"2001","unstructured":"Keane J, Gershon S, Wise RP, Mirabile-Levens E, Kasznica J, Schwieterman WD, et al. Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med. 2001;345:1098\u2013104.","journal-title":"N Engl J Med"},{"key":"1793_CR41","doi-asserted-by":"publisher","first-page":"602","DOI":"10.1038\/ncprheum0336","volume":"2","author":"KL Winthrop","year":"2006","unstructured":"Winthrop KL. Risk and prevention of tuberculosis and other serious opportunistic infections associated with the inhibition of tumor necrosis factor. Nat Clin Pract Rheumatol. 2006;2:602\u201310.","journal-title":"Nat Clin Pract Rheumatol"},{"key":"1793_CR42","first-page":"93","volume":"26","author":"H Saricaoglu","year":"2004","unstructured":"Saricaoglu H, Bulbul EB, Cikman ST, Dilek K, Tunali S. Effects of long-term cyclosporine A therapy on renal functions in Beh\u00e7et's disease. Int J Tissue React. 2004;26:93\u20136.","journal-title":"Int J Tissue React"},{"key":"1793_CR43","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1016\/S0161-6420(99)90120-3","volume":"106","author":"S Kotake","year":"1999","unstructured":"Kotake S, Higashi K, Yoshikawa K, Sasamoto Y, Okamoto T, Matsuda H. Central nervous system symptoms in patients with Beh\u00e7et disease receiving cyclosporine therapy. Ophthalmology. 1999;106:586\u20139.","journal-title":"Ophthalmology"},{"key":"1793_CR44","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1007\/s00417-005-0005-8","volume":"243","author":"M Takeuchi","year":"2005","unstructured":"Takeuchi M, Hokama H, Tsukahara R, Kezuka T, Goto H, Sakai J, et al. Risk and prognostic factors of poor visual outcome in Behcet\u2019s disease with ocular involvement. Graefes Arch Clin Exp Ophthalmol. 2005;243:1147\u201352.","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"1793_CR45","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1007\/s00417-009-1234-z","volume":"248","author":"T Kaburaki","year":"2010","unstructured":"Kaburaki T, Araki F, Takamoto M, et al. Best-corrected visual acuity and frequency of ocular attacks during the initial 10 years in patients with Beh\u00e7et\u2019s disease. Graefes Arch Clin Exp Ophthalmol. 2010;248:709\u201314.","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"1793_CR46","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1136\/ard.2006.056804","volume":"66","author":"K Fujikawa","year":"2007","unstructured":"Fujikawa K, Aratake K, Kawakami A, et al. Successful treatment of refractory neuro-Beh\u00e7et\u2019s disease with infliximab: a case report to show its efficacy by magnetic resonance imaging, profile transcranial magnetic stimulation and cytokine. Ann Rheum Dis. 2007;66:136\u20137.","journal-title":"Ann Rheum Dis"},{"key":"1793_CR47","doi-asserted-by":"publisher","first-page":"1259","DOI":"10.1002\/ibd.20457","volume":"14","author":"M Naganuma","year":"2008","unstructured":"Naganuma M, Sakuraba A, Hisamatsu T, et al. Efficacy of infliximab for induction and maintenance of remission in intestinal Beh\u00e7et\u2019s disease. Inflamm Bowel Dis. 2008;14:1259\u201364.","journal-title":"Inflamm Bowel Dis"},{"key":"1793_CR48","doi-asserted-by":"publisher","first-page":"744","DOI":"10.1136\/ard.2003.010975","volume":"63","author":"G Haugeberg","year":"2004","unstructured":"Haugeberg G, Velken M, Johnsen V. Successful treatment of genital ulcers with infliximab in Beh\u00e7et\u2019s disease. Ann Rheum Dis. 2004;63:744\u20135.","journal-title":"Ann Rheum Dis"},{"key":"1793_CR49","doi-asserted-by":"publisher","first-page":"e3863","DOI":"10.1097\/MD.0000000000003863","volume":"95","author":"T Hibi","year":"2016","unstructured":"Hibi T, Hirohata S, Kikuchi H, Tateishi U, Sato N, Ozaki K, et al. Infliximab therapy for intestinal, neurological, and vascular involvement in Behcet disease: efficacy, safety, and pharmacokinetics in a multicenter, prospective, open-label, single-arm phase 3 study. Medicine (Baltimore). 2016;95:e3863.","journal-title":"Medicine (Baltimore)"}],"container-title":["Arthritis Research & Therapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13075-018-1793-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s13075-018-1793-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13075-018-1793-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,13]],"date-time":"2024-07-13T20:53:10Z","timestamp":1720903990000},"score":1,"resource":{"primary":{"URL":"https:\/\/arthritis-research.biomedcentral.com\/articles\/10.1186\/s13075-018-1793-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1,5]]},"references-count":49,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["1793"],"URL":"https:\/\/doi.org\/10.1186\/s13075-018-1793-7","relation":{},"ISSN":["1478-6362"],"issn-type":[{"value":"1478-6362","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,1,5]]},"assertion":[{"value":"31 July 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 December 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 January 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This PMS study protocol was approved by the Ministry of Health, Labor and Welfare of the Japan Government, and was conducted in accordance with good post-marketing surveillance practice (GPSP), which sets the standard for PMS studies of approved drugs in clinical practice. Patients were treated in accordance with physicians\u2019 usual clinical practice and indication for commercially available IFX.; no consent was needed by the institutions\u2019 ethics committees.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"SO has received expert testimony fees from Mitsubishi Tanabe Pharma Corporation, AbbVie GK, Alcon Japan, Bosch & Lomb Japan, and Santen Pharmaceutical Company; grants\/research support from Mitsubishi Tanabe Pharma Corporation; lecture fees from Mitsubishi Tanabe Pharma Corporation, Alcon Japan, Otsuka Pharmaceutical Company, and Santen Pharmaceutical Company; patent fees from Mitsubishi Tanabe Pharma Corporation. IU, MM, TG, and TY are full-time employees of Mitsubishi Tanabe Pharma Corporation.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"2"}}